Martin Schaefer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Schaefer has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Heinz
Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
7 shared publications Axel Hinzpeter
Charité—Universitätsmedizin Berlin, Klinik und Poliklinik für Psychiatrie und Psychotherapie—Campus Charité Mitte, Berlin, Germany
3 shared publications- Markus Schwaiger
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
3 shared publications Astrid Friebe
2 shared publicationsFolkhard Schmidt
Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstr. 7, D-80336 Munich, Germany
2 shared publicationsMaurice Pich
Charité—Universitätsmedizin Berlin, Klinik und Poliklinik für Psychiatrie und Psychotherapie—Campus Charité Mitte, Berlin, Germany
2 shared publications
Latest Publications
- 1 September 2008
- Published by Elsevier in Psychosomatics
- Vol. 49 (5) , 442-446
Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFNα-Associated Mood Disorders
- 1 September 2008
- Published by Elsevier in Psychosomatics
- Vol. 49 (5) , 442-446
Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFNα-Associated Mood Disorders
- Open Access
- 1 August 2007
- Published by Wolters Kluwer Health in Hepatology
- Vol. 46 (4) , 991-998
Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin
We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric-risk patients and controls with pegylated interferon alpha (pegIFN-α) plus ribavirin. Seventy patients were prospectively screened for psychiatric disorders. Seventeen patients without psychiatric diseases or drug addiction (controls), 22 patients with psychiatric disorders, 18 patients who had received methadone substitution treatment and 13 patients who were former drug users were treated with pegIFN-α plus ribavirin. Sustained virological response (SVR), adherence, and psychiatric side effects (using the Montgomery-Asberg Depression Rating Scale and the Brief Psychiatric Rating Scale) in the groups were compared. An SVR was found in 58.6% of all patients: 58.8% of the controls, 50% of psychiatric patients, 72.2% of methadone patients, and 53.8% of former drug users. Methadone-substituted patients and former drug users had significantly higher dropout rates. Scores for neither depressive nor psychotic symptoms differed significantly between groups during treatment. However, the controls had lower pretreatment scores, followed by a significant higher increase to maximum scores. A stepwise logistic regression model showed that only genotype, not group (control, psychiatric, methadone, or former drug abuse), type of psychiatric diagnosis (affective disorder, personality disorder, or schizophrenic disorder), depression scores before and during treatment, change in depression score, antidepressive treatment, sex, or liver enzymes before treatment, was associated with SVR. Conclusion: In an interdisciplinary treatment setting psychiatric diseases and/or drug addiction did not negatively influence psychiatric tolerability of and antiviral response rate to HCV treatment with pegIFN-α and ribavirin. (HEPATOLOGY 2007.)
- 1 August 2007
- Published by Wolters Kluwer Health in Hepatology
- Vol. 46 (4) , 991-998
Open AccessHepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin
We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric-risk patients and controls with pegylated interferon alpha (pegIFN-α) plus ribavirin. Seventy patients were prospectively screened for psychiatric disorders. Seventeen patients without psychiatric diseases or drug addiction (controls), 22 patients with psychiatric disorders, 18 patients who had received methadone substitution treatment and 13 patients who were former drug users were treated with pegIFN-α plus ribavirin. Sustained virological response (SVR), adherence, and psychiatric side effects (using the Montgomery-Asberg Depression Rating Scale and the Brief Psychiatric Rating Scale) in the groups were compared. An SVR was found in 58.6% of all patients: 58.8% of the controls, 50% of psychiatric patients, 72.2% of methadone patients, and 53.8% of former drug users. Methadone-substituted patients and former drug users had significantly higher dropout rates. Scores for neither depressive nor psychotic symptoms differed significantly between groups during treatment. However, the controls had lower pretreatment scores, followed by a significant higher increase to maximum scores. A stepwise logistic regression model showed that only genotype, not group (control, psychiatric, methadone, or former drug abuse), type of psychiatric diagnosis (affective disorder, personality disorder, or schizophrenic disorder), depression scores before and during treatment, change in depression score, antidepressive treatment, sex, or liver enzymes before treatment, was associated with SVR. Conclusion: In an interdisciplinary treatment setting psychiatric diseases and/or drug addiction did not negatively influence psychiatric tolerability of and antiviral response rate to HCV treatment with pegIFN-α and ribavirin. (HEPATOLOGY 2007.)
- 1 July 2007
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 40 (4) , 149-151
Memantine-associated Reversal of Clozapine-induced Weight Gain
Introduction: Weight gain is a frequently observed adverse event in the treatment with atypical antipsychotics that significantly affects the patients’ physical health and treatment compliance. Methods: We report on a treatment-resistant schizophrenic patient who received an add-on treatment with the low-affinity NMDA antagonist memantine because of cognitive disturbances. Results: During this treatment we observed a marked decrease of clozapine-induced weight gain. The causal relationship to memantine could be demonstrated using an on-off-on design with a significant increase of weight after discontinuation and again a substantial weight loss after re-exposition with memantine. Beside weight, also negative symptoms improved. Discussion: Prospective controlled trials evaluating the safety and possible positive effects of memantine on antipsychotic induced weight gain are needed.
- 1 July 2007
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 40 (4) , 149-151
Memantine-associated Reversal of Clozapine-induced Weight Gain
Introduction: Weight gain is a frequently observed adverse event in the treatment with atypical antipsychotics that significantly affects the patients’ physical health and treatment compliance. Methods: We report on a treatment-resistant schizophrenic patient who received an add-on treatment with the low-affinity NMDA antagonist memantine because of cognitive disturbances. Results: During this treatment we observed a marked decrease of clozapine-induced weight gain. The causal relationship to memantine could be demonstrated using an on-off-on design with a significant increase of weight after discontinuation and again a substantial weight loss after re-exposition with memantine. Beside weight, also negative symptoms improved. Discussion: Prospective controlled trials evaluating the safety and possible positive effects of memantine on antipsychotic induced weight gain are needed.
- 1 June 2006
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 26 (3) , 347-349
Levetiracetam for the Treatment of Alcohol Withdrawal Syndrome
- 1 June 2006
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 26 (3) , 347-349
Levetiracetam for the Treatment of Alcohol Withdrawal Syndrome
- 1 June 2005
- Published by Elsevier in Journal of Hepatology
- Vol. 42 (6) , 793-798
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C
- 1 June 2005
- Published by Elsevier in Journal of Hepatology
- Vol. 42 (6) , 793-798
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C
- 1 November 2004
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 18 (6) , 555-562
Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α
- 1 November 2004
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 18 (6) , 555-562
Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
Aims Approximately 170 million people world‐wide are chronically infected with the hepatitis C virus (HCV). While the seroprevalence in the general population ranges between 0.2 and 2%, 50–90% of injection drug users are chronically HCV‐infected. However, most patients who are drug abusers are still excluded from treatment of chronic HCV infection with interferon (IFN)‐α. Due to the recent treatment advances resulting in sustained response rates between 50 and 80%, it becomes increasingly important to reflect the still existing contraindications and restrictions for IFN‐α treatment, especially for patients with intravenous drug use (IDU) with or without psychiatric comorbidity.Methods We reviewed clinical trials that focus on the treatment of chronic hepatitis C in patients with drug addiction published between 1987 and 2003.Findings Only seven clinical trials investigating HCV treatment among drug users were found: four open prospective uncontrolled trials and three controlled trials. Thus far, no trials using pegylated IFN‐α have been conducted. Data about sustained response and adherence in HCV‐infected methadone substituted patients were either comparable to control groups or to representative clinically controlled trials using the same treatment regimen (IFN‐α monotherapy or combined with ribavirin). Patients with former or present drug abuse seem more likely to discontinue treatment early. HCV‐infected IDUs tended to be older with higher inflammatory activity and stage of fibrosis when interferon treatment was started. Psychiatric comorbidity did not negatively influence adherence or treatment outcome.Conclusions There is no clinical evidence suggesting that HCV treatment with IFN‐α should be limited to IDUs or methadone substituted patients. However, more prospective controlled trials on HCV treatment for patients with IDU are needed to establish and apply new rules and guidelines.
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
Aims Approximately 170 million people world‐wide are chronically infected with the hepatitis C virus (HCV). While the seroprevalence in the general population ranges between 0.2 and 2%, 50–90% of injection drug users are chronically HCV‐infected. However, most patients who are drug abusers are still excluded from treatment of chronic HCV infection with interferon (IFN)‐α. Due to the recent treatment advances resulting in sustained response rates between 50 and 80%, it becomes increasingly important to reflect the still existing contraindications and restrictions for IFN‐α treatment, especially for patients with intravenous drug use (IDU) with or without psychiatric comorbidity.Methods We reviewed clinical trials that focus on the treatment of chronic hepatitis C in patients with drug addiction published between 1987 and 2003.Findings Only seven clinical trials investigating HCV treatment among drug users were found: four open prospective uncontrolled trials and three controlled trials. Thus far, no trials using pegylated IFN‐α have been conducted. Data about sustained response and adherence in HCV‐infected methadone substituted patients were either comparable to control groups or to representative clinically controlled trials using the same treatment regimen (IFN‐α monotherapy or combined with ribavirin). Patients with former or present drug abuse seem more likely to discontinue treatment early. HCV‐infected IDUs tended to be older with higher inflammatory activity and stage of fibrosis when interferon treatment was started. Psychiatric comorbidity did not negatively influence adherence or treatment outcome.Conclusions There is no clinical evidence suggesting that HCV treatment with IFN‐α should be limited to IDUs or methadone substituted patients. However, more prospective controlled trials on HCV treatment for patients with IDU are needed to establish and apply new rules and guidelines.
- 15 December 2003
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 36 (S 3) , 203-206
Neurotransmitter Changes by Interferon-Alpha and Therapeutic Implications
Interferon alpha (IFN-α) is a cytokine that is widely used for the treatment of chronic viral infection or malignant disorders. During treatment with IFN-α, severe neuropsychiatric syndromes may occur such as depression with suicidal ideation, paranoid psychoses or confusional states. The neurobiological correlates of these side effects are widely unknown. Besides induction of other cytokines and hormonal changes, IFN-α has been shown to modulate the opioid, serotonin, dopamine and glutamate neurotransmitter system. Positive therapeutic effects of antidepressants such as selective serotonin-reuptake-inhibitors (SSRI) or of opioid receptor antagonists support the hypothesis that neurotransmitter changes play an important role in the development of IFN-α associated neuropsychiatric side effects. We review recent research about IFN-associated neurotransmitter changes in the central nervous system and discuss treatment strategies.
- 15 December 2003
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 36 (S 3) , 203-206
Neurotransmitter Changes by Interferon-Alpha and Therapeutic Implications
Interferon alpha (IFN-α) is a cytokine that is widely used for the treatment of chronic viral infection or malignant disorders. During treatment with IFN-α, severe neuropsychiatric syndromes may occur such as depression with suicidal ideation, paranoid psychoses or confusional states. The neurobiological correlates of these side effects are widely unknown. Besides induction of other cytokines and hormonal changes, IFN-α has been shown to modulate the opioid, serotonin, dopamine and glutamate neurotransmitter system. Positive therapeutic effects of antidepressants such as selective serotonin-reuptake-inhibitors (SSRI) or of opioid receptor antagonists support the hypothesis that neurotransmitter changes play an important role in the development of IFN-α associated neuropsychiatric side effects. We review recent research about IFN-associated neurotransmitter changes in the central nervous system and discuss treatment strategies.
- 1 February 2003
- Published by Wolters Kluwer Health in Hepatology
- Vol. 37 (2) , 443-451
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of interferon alfa (IFN-α) in patients with chronic hepatitis C. Our aim was to obtain prospective data on adherence to as well as efficacy and mental side effects of treatment with IFN-α in different psychiatric risk groups compared with controls. In a prospective trial, 81 patients with chronic hepatitis C (positive hepatitis C virus[HCV] RNA and elevated alanine aminotransferase[ALT] level) and psychiatric disorders (n = 16), methadone substitution (n = 21), former drug addiction (n = 21), or controls without a psychiatric history or drug addiction (n = 23) were treated with a combination of IFN-α-2a 3 MU 3 times weekly and ribavirin (1,000-1,200 mg/d). Sustained virologic response (overall, 37%) did not differ significantly between subgroups. No significant differences between groups were detected with respect to IFN-α-related development of depressions during treatment. However, in the psychiatric group, significantly more patients received antidepressants before and during treatment with IFN-α (P < .001). Most of those who dropped out of the study were patients with former drug addiction (43%; P = .04) compared with 14% in the methadone group, 13% in the control group, and 18% in the psychiatric group. No patient in the psychiatric group had to discontinue treatment because of psychiatric deterioration. In conclusion, our data do not confirm the supposed increased risk for IFN-α-induced mental side effects and dropouts in psychiatric patients if interdisciplinary care and antidepressant treatment are available. Preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-α and ribavirin in an interdisciplinary setting.
- 1 February 2003
- Published by Wolters Kluwer Health in Hepatology
- Vol. 37 (2) , 443-451
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of interferon alfa (IFN-α) in patients with chronic hepatitis C. Our aim was to obtain prospective data on adherence to as well as efficacy and mental side effects of treatment with IFN-α in different psychiatric risk groups compared with controls. In a prospective trial, 81 patients with chronic hepatitis C (positive hepatitis C virus[HCV] RNA and elevated alanine aminotransferase[ALT] level) and psychiatric disorders (n = 16), methadone substitution (n = 21), former drug addiction (n = 21), or controls without a psychiatric history or drug addiction (n = 23) were treated with a combination of IFN-α-2a 3 MU 3 times weekly and ribavirin (1,000-1,200 mg/d). Sustained virologic response (overall, 37%) did not differ significantly between subgroups. No significant differences between groups were detected with respect to IFN-α-related development of depressions during treatment. However, in the psychiatric group, significantly more patients received antidepressants before and during treatment with IFN-α (P < .001). Most of those who dropped out of the study were patients with former drug addiction (43%; P = .04) compared with 14% in the methadone group, 13% in the control group, and 18% in the psychiatric group. No patient in the psychiatric group had to discontinue treatment because of psychiatric deterioration. In conclusion, our data do not confirm the supposed increased risk for IFN-α-induced mental side effects and dropouts in psychiatric patients if interdisciplinary care and antidepressant treatment are available. Preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-α and ribavirin in an interdisciplinary setting.